Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > WhiskeyBoozer

<< Previous

Bullboard Posts

Next >>

Post by polygraph46on Mar 12, 2021 1:01am

315 Views

Post# 32783043

Re: WhiskeyBoozer

Scotty:
Don't even attempt discourse re above subject. You are dealing with thick thick layers. Did you

ever hear the statement: "a little knowledge is a dangerous thing". Well, that's an apt description.

Looks like he's mixing the cool aid of the day with his Crown Royale. Could cause a problem with

the innards down the road......be careful .....pg46

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week